Current Report Filing (8-k)
March 01 2017 - 4:37PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): March 1, 2017
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 1, 2017,
Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing
its financial results for the quarter and year ended December 31, 2016. A copy of the Press Release is furnished herewith
as Exhibit 99.1.
On February 22, 2017,
Nektar announced that it would hold a Webcast conference call on March 1, 2017 to review its financial results for the quarter
and year ended December 31, 2016 and give an update on its business. This conference call is accessible through a link that is
posted on the home page and Investor section of the Nektar website:
http://www.nektar.com
.
The information in
this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not
be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release titled “Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results” issued by Nektar Therapeutics on March 1, 2017.
|
SIGNATURES
Pursuant to the requirement of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
By:
|
/s/ Mark A. Wilson
|
|
|
|
Mark A. Wilson
|
|
|
|
General Counsel and Secretary
|
|
|
|
|
|
Date:
|
March 1, 2017
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release titled “Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results” issued by Nektar Therapeutics on March 1, 2017.
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2023 to Apr 2024